Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.Read the factsheet
ECDC guidance on HPV vaccination in EU countries
This guidance partly complements and updates the 2008 and 2012 guidance documents on the introduction of HPV immunisation in EU/EEA Member States. It also covers the efficacy of the 9-valent vaccine, which was not licensed when the last guidance was published.Read the guidance
European Immunization Week, 2020
The campaign is marked across Europe every April and aims to raise awareness of the importance of immunisation. ECDC supports the week by launching a new European Vaccination Information Portal with up to date information on human papillomavirus.Read more
Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction
Human papillomavirus vaccination coverage, policies, and practical implementation across Europe
HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV
Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.
Prevention and control
Two prophylactic HPV vaccines have been licensed in Europe, a bivalent and a quadrivalent vaccine: both have a good safety profile and protect against the high-risk HPV types 16 and 18.